of innovative drug candidate for neurodegenerative diseases
Good safety profile and significant pharmacological effects confirm NX210c drug candidate properties and potential to address broad range of neurodegenerative diseases
Biomarkers reveal significant and sustained effects confirming NX210c’s action on integrity and repair of Blood Brain Barrier (BBB), as well as fundamental pathways in neuroprotection and neurotransmission
In 2024, Axoltis plans to initiate phase 2 trial in patients with Amyotrophic Lateral Sclerosis (ALS) and conduct phase 1b trial in Parkinson’s Disease (PD) while performing in silico modeling to further evaluate and optimize potential of NX210c more broadly in neurodegenerative diseases
Clermont-Ferrand and Lyon, France, December 12, 2023 – Axoltis Pharma, a French biopharmaceutical company dedicated to developing therapeutic solutions for neurodegenerative diseases, today announces promising results from its phase 1b clinical trial evaluating NX210c, a patented peptide drug candidate. These results follow a single-ascending dose phase 1a study carried out in 2020, which had demonstrated a good safety profile for NX210c in healthy volunteers.